) has been infected with a plague of negative earnings surprises.
The company has posted only one positive surprise in the last seven
quarters and has seen earnings estimates decline. The stock is a
Zacks Rank #4 (Sell) and is the Bear of the Day.
Negative Earnings Surprises
The company is currently riding a streak of four negative earnings
surprises, and has missed in six of the last seven quarters.
Investors generally want management to have a better handle on
handling the expectations of Wall Street.
The misses are small, but they are misses nonetheless. The June
2012 quarter saw a 5.8% miss while the September 2012 quarter
missed by 5%. The December 2012 quarter posted a negative earnings
surprise of 2.6% and that was followed by the most recent miss of
1.1% for the March 2013 quarter that was posted on April 30.
Expectations on the top line have seen similar trouble, with the
company coming in light on the top line in each of the misses by as
much as $3M or 3.1% and as little as $1M or 1.7%.
Techne makes biotechnology research & diagnostic products and
hematology calibrators and controls. The company was founded in
1976 and is headquartered in Minneapolis, Minnesota.
Over the last four quarters, TECG has posted a negative earnings
surprise in each quarter. This has led to a lowering of expected
earnings, a key component investors use to determine a buy from a
sell. The Zacks Consensus estimate for 2013 was $3.49 in June 2012,
it tailed off follow each earnings report. The estimate is
currently at $3.19 after dropping another $0.02 from last month.
The 2014 earnings estimates aren't being spared. They have moved
from $3.67 to $3.31 over the same time period. A more dramatic
recent reduction saw the estimates move from $3.37 in April to its
The lower estimates and earnings will typically inflate the
valuation metrics if the stock is not moving lower as well. That is
the case here as TECH is trading at 21x trailing earnings while the
industry average is 18.7x. The forward PE of 20.9x is also higher
than the 18.3x industry average. The price to book at 3.4x is
slightly higher than the 3.2x industry average while price to sales
of 8x is well above the 2.6x industry average.
The 3 month chart below shows the stock trading off but also
rebounding of late. Investors would be wise to show caution and
take a hard look at other comparable companies before making any
decision on an investment in TECH.
Brian Bolan is a Stock Strategist for Zacks.com. He is the Editor
in charge of the
Run Investor service
, a Buy and Hold service where he recommends the stocks in the
Brian is also the editor of
a trading service that focuses on small cap stocks and also carries
a risk limiting strategy.
Follow Brian Bolan
Like Brian Bolan
TECHNE CORP (TECH): Free Stock Analysis Report
To read this article on Zacks.com click here.